"Abigan" could not confirm the effectiveness clearly Fujita Medical University, etc. New Corona July 10 15:57
A group such as Fujita Medical University in Aichi Prefecture said that it was not possible to confirm clear efficacy in clinical studies administered to patients with "Abigan", which is expected as a candidate for a new coronavirus therapeutic agent. Announced.
Since March, groups such as Fujita Medical University have been conducting clinical studies to verify the efficacy and safety of 88 patients with mild or asymptomatic inpatients who received “Abigan”, a drug for influenza treatment. The results were announced at an online interview on Sunday.
The clinical studies are conducted by comparing the "group receiving Avigan for up to 10 days from the first day" with the "group receiving no administration for the first 5 days after the 6th day of hospitalization".
According to the announcement, in the "group administered from the first day", 66.7% of patients did not detect the virus by the 6th day, but in the "group not administered for 5 days" 56.1%.
Also, the average number of days it took for the fever to drop was 2.1 days after administration from the first day and 3.2 days without administration for 5 days.
The study group found that administration of the drug from the first day of hospitalization tended to eliminate the virus and reduce fever, but the statistically clear efficacy could not be confirmed.
On the other hand, no serious side effects could be confirmed.
Prof. Yohei Doi said, "I don't think it was a conclusion that there was a tendency to improve quickly and that it was not effective. I would like to provide data to the country upon request."
Ministry of Health, Labor and Welfare “Pharmaceutical company decides whether to apply”
In response to the results of a clinical study conducted by Fujita Medical University regarding "Abigan", the Ministry of Health, Labor and Welfare said, "How do you handle this result and whether you will apply for approval as a new coronavirus treatment in the future? It is the decision of the pharmaceutical company. If an application is submitted, the Ministry of Health, Labor and Welfare will need to consider it again."